Evidence map›Paper›PMID 41967115›Full record

ArticleJNCI cancer spectrum2026

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

P Travis Courtney, Ya-Chen Tina Shih, Albert J Chang, Alan Lee, Michael L Steinberg, Luca F Valle, Puja S Venkat, Amar U Kishan, Ann C Raldow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JNCI cancer spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

P Travis CourtneyDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.ORCID 0000-0001-7625-3678
Ya-Chen Tina ShihDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Albert J ChangDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Alan LeeDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Michael L SteinbergDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Luca F ValleDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.ORCID 0000-0002-5781-4174
Puja S VenkatDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Amar U KishanDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.
Ann C RaldowDepartment of Radiation Oncology, University of California, Los Angeles, CA, United States.ORCID 0000-0001-8996-6810

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ArteraAI Prostate Test (ArteraAI Inc.) is the first predictive biomarker for the benefit of adding short-term androgen deprivation therapy (ADT) to radiotherapy for intermediate-risk prostate cancer. We evaluated the cost-effectiveness of ArteraAI to guide short-term ADT using a Markov model simulating 15-year outcomes for 71-year-old patients with intermediate-risk prostate cancer receiving radiotherapy using NRG/RTOG 9408 data on which ArteraAI was validated. Three strategies were compared: (1) all patients receive ADT (ADT-for-all), (2) only patients with unfavorable intermediate-risk prostate cancer receive ADT (National Comprehensive Cancer Network [NCCN]), and (3) only ArteraAI-positive patients receive ADT (ArteraAI). Costs and utilities obtained from Medicare claims and published literature were used to calculate incremental cost-effectiveness ratios. A willingness-to-pay threshold of $100 000/quality-adjusted life year (QALY) was chosen. The ADT-for-all strategy was dominated by the NCCN strategy. Compared with the NCCN strategy, the ArteraAI strategy lowered costs by $12 296 and improved effectiveness by 0.01 QALYs making it dominant.

Indexed as

Androgen AntagonistsArtificial IntelligenceCost-Benefit AnalysisCost-Effectiveness AnalysisProstatic NeoplasmsAgedHumansMaleMarkov ChainsMedicareQuality-Adjusted Life YearsAndrogen Antagonists

Identifiers

PMID41967115
PMCPMC13127416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.